Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (not Cypherpunk Technologies Inc.) on September 16, 2019, covering events reported on September 17, 2019. The registrant is a Delaware corporation listed on the Nasdaq Global Market under the symbol LPTX and is classified as an emerging growth company.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding clinical trial data and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
There are no financial material changes reported in this document. The material event is the inadvertent early release of a corporate poster presentation containing updated clinical data from the Company's ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies.
Guidance, Outlook, and Management Commentary
- Event: The Company confirmed it will present at the 2019 International Gynecologic Cancer Society Annual Global Meeting (IGCS Conference) on September 20, 2019, in Rio de Janeiro, Brazil.
- Disclosure Reason: The report was filed to satisfy Regulation FD obligations because the presentation materials were inadvertently made available on the IGCS Conference website prior to the scheduled presentation.
- Legal Status: The information is furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934 and will not be incorporated by reference into registration statements unless specifically identified.
Investor Verification Checklist
- Verify the clinical data details in the attached Exhibit 99.1 (Press Release dated September 17, 2019).
- Confirm the presentation schedule at the IGCS Conference in Rio de Janeiro.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.
- Confirm the company name is Leap Therapeutics, Inc., as the input metadata contained an incorrect company name.